Eindhoven based med-tech start-up company Plasmacure, developing a chronic wound healing device Plasoma, closed a series A round of funding. The funding was raised with private investors, NextGen Ventures and East Netherlands Development Agency – Oost NL. NextGen Ventures is a fund built primarily on investments by the healthcare insurers Menzis and Friesland Zorgverzekeraar. The amount of funding has not been disclosed.
Plasmacure will use the investment to get CE marking and introduce the product to the market. The first focus is on diabetic foot wounds. This funding will support Plasmacure in developing the device for home use, and for treating other types of wounds.
“This funding is very important for us because it will enable us to bring the device to the people who need it and for whom there is no real help at this moment. We realize that we can really start helping these people and this feels great” – said the CEO and founder of the company, Bas Zeper.
More on Plasmacure here (more after the video)
The primary reason for Oost NL to invest in Plasmacure is that it makes healthcare more affordable. Treating persistently open wounds costs the Dutch healthcare budget €2 billion. Pieter Rhemrev, manager of the business unit Capital at Oost NL, says, “Plasmacure is handy, takes very little time to apply and is painless. It clearly advances the quality of life for the patient. With this investment, we are promoting result-oriented healthcare”.
Plasmacure has already shown its potential – and results – after the first clinical trial at VU Medical Center Amsterdam. This study with the participation of 20 patients demonstrated that more than half of the wounds reduced in size and two wounds (10%) healed completely during the two weeks treatment period.